Highlights Reviva Pharmaceuticals Holdings, Inc.

Equities

RVPH

US76152G1004

Market Closed - Nasdaq Other stock markets 01:30:00 19/06/2024 am IST			5-day change	1st Jan Change
1.37 ^USD	-5.52%		-9.27%	-73.40%

11/06	HC Wainwright Adjusts Price Target on Reviva Pharmaceuticals Holdings to $14 From $20, Maintains Buy Rating	MT
28/05	Riviva Pharmaceuticals Prices $3 Million Offering of Stock, Warrants; Shares Slump	MT

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Riviva Pharmaceuticals Prices $3 Million Offering of Stock, Warrants; Shares Slump	28/05	MT
Reviva Pharmaceuticals Holdings, Inc. Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia	15/05	CI
Reviva Pharmaceuticals Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	14/05	CI
Reviva Pharmaceuticals Holdings, Inc. to Present New Preclinical Efficacy Data on Brilaroxazine in Idiopathic Pulmonary Fibrosis at 2024 ATS International Conference	13/05	CI
Reviva Pharmaceuticals Holdings, Inc. Gains Alignment with U.S. Food and Drug Administration on its Registrational Phase 3 Program for Brilaroxazine in Schizophrenia	15/04	CI
Reviva Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	15/04	CI
Reviva Pharmaceuticals to Seek Acquisitions	16/11	CI
Reviva Pharmaceuticals Holdings Q3 Loss Widens	15/11	MT
Reviva Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	15/11	CI
Reviva Pharma's schizophrenia drug succeeds in late-stage study	30/23/30	RE
Reviva Announces Positive Topline Results from Global Pivotal Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia	30/23/30	CI
Reviva Pharmaceuticals Holdings, Inc. Announces Enrollment Completion for Pivotal Phase 3 Recover Study for Brilaroxazine in Schizophrenia	17/23/17	CI
Reviva Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	15/23/15	CI
Reviva Pharmaceuticals Holdings, Inc. Announces 80% Global Enrollment Update for Pivotal Phase 3 RECOVER Study Evaluating Brilaroxazine for Schizophrenia	22/23/22	CI
Reviva Pharmaceuticals Holdings, Inc Joins Webull Corporate Communications Service Platform	19/23/19	CI
Reviva Pharmaceuticals Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	16/23/16	CI
Reviva Pharmaceuticals Presents Foundational Preclinical Data on Novel Serotonin-Dopamine Stabilizer Brilaroxazine at the 78th Annual SOBP and Publication in Medical Research Archives	02/23/02	CI
Fed Rate Increase Drags Exchange-Traded Funds, Stock Futures Lower Premarket Thursday	15/22/15	MT
Reviva Pharmaceuticals Holdings, Inc. Announces Positive Safety Data from Drug-Drug Interaction Clinical Study of Brilaroxazine	15/22/15	CI
Reviva Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	15/22/15	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Reviva Pharmaceuticals Holdings, Inc.

Equities

RVPH

US76152G1004

Highlights

Filters